Infectious Disease Diagnostics

Global Infectious Disease Diagnostics Market to Reach US$41.1 Billion by 2032

The global market for Infectious Disease Diagnostics estimated at US$22.7 Billion in the year 2025, is expected to reach US$41.1 Billion by 2032, growing at a CAGR of 8.8% over the analysis period 2025-2032. Reagents / Kits / Consumables Component, one of the segments analyzed in the report, is expected to record a 8.8% CAGR and reach US$17.4 Billion by the end of the analysis period. Growth in the Instruments Component segment is estimated at 10.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$7.0 Billion While China is Forecast to Grow at 13.8% CAGR

The Infectious Disease Diagnostics market in the U.S. is estimated at US$7.0 Billion in the year 2025. China, the world`s second largest economy, is forecast to reach a projected market size of US$10.7 Billion by the year 2032 trailing a CAGR of 13.8% over the analysis period 2025-2032. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.9% and 8.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.3% CAGR.

Infectious Disease Diagnostics Market - Key Trends & Drivers Summarized

What Are Infectious Disease Diagnostics and Why Are They Fundamental to Public Health?

Infectious disease diagnostics comprise tests and procedures used to identify the presence of pathogens like bacteria, viruses, fungi, or parasites in human samples. These diagnostics are fundamental to public health as they enable early detection, diagnosis, and management of infections, thereby preventing their spread and reducing morbidity and mortality. Technologies utilized include traditional culture techniques, serological assays, and advanced molecular methods like polymerase chain reaction (PCR) and next-generation sequencing. These tools are vital in outbreak situations, such as the COVID-19 pandemic, where rapid identification and isolation of cases are critical. The effectiveness of diagnostics is continually enhanced by advancements in biomedical science, contributing to more accurate, faster, and cost-effective tests.

How Is Technological Advancement Shaping the Landscape of Infectious Disease Diagnostics?

The landscape of infectious disease diagnostics is being reshaped by significant technological advancements. Innovations such as point-of-care (POC) testing devices allow for rapid, on-site diagnosis without the need for specialized laboratory facilities, making it easier to diagnose diseases in remote or resource-limited settings. Additionally, the integration of digital health technologies, including health information systems that track disease outbreaks in real time, is improving the efficiency of disease surveillance and response. Molecular diagnostic techniques, particularly PCR and CRISPR-based diagnostics, have revolutionized the field by providing high sensitivity and specificity in detecting pathogens. These advancements not only enhance diagnostic capabilities but also facilitate personalized treatment approaches, tailoring interventions to individual patient needs based on diagnostic results.

What Global Trends Are Influencing the Infectious Disease Diagnostics Market?

Several global trends are influencing the infectious disease diagnostics market, notably the increasing incidence of infectious diseases and the resurgence of conditions such as tuberculosis and malaria. Urbanization and global travel contribute to the rapid spread of infections, highlighting the need for effective diagnostic tools. Climate change also plays a role, as changing temperatures and precipitation patterns affect the distribution of vector-borne diseases, increasing the demand for diagnostics. Furthermore, the rise in antimicrobial resistance is prompting the development of diagnostics that can quickly identify resistant pathogens and guide appropriate treatment decisions. These trends necessitate robust, scalable diagnostic solutions that can be deployed globally to manage both endemic diseases and emerging infections.

Growth in the Infectious Disease Diagnostics Market Is Driven by Several Factors

The growth in the infectious disease diagnostics market is driven by several factors, including technological innovations, epidemiological shifts, and healthcare infrastructure developments. Technological advances that offer quicker, more accurate, and cost-effective diagnostic tests are crucial, as they improve the capacity to manage outbreaks and endemic diseases effectively. The increasing global burden of infectious diseases, driven by factors such as increased international travel and urbanization, also plays a significant role in fueling the demand for advanced diagnostics. Additionally, government and healthcare policies focusing on preventive care and early diagnosis are significantly influencing market expansion. Investments in healthcare infrastructure, particularly in developing regions, are enabling wider access to diagnostic services, further propelling market growth. Consumer behavior, especially heightened awareness regarding health and preventive measures following the COVID-19 pandemic, continues to drive the adoption of these diagnostics in routine healthcare practices. These combined factors underscore the dynamic expansion of the infectious disease diagnostics market, reflecting a global shift towards more proactive and preventive healthcare strategies.

SCOPE OF STUDY:

The report analyzes the Infectious Disease Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product (Assays & Reagents, Instruments, Software); Technology (Immunodiagnostics, Clinical Microbiology, PCR, INAAT, DNA Sequencing & NGS, DNA Microarray, Other Technologies)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

SELECT PLAYERS -

• Abbott Laboratories
• Becton, Dickinson and Company
• bioMerieux SA
• Bio-Rad Laboratories, Inc.
• Danaher Corporation
• DiaSorin SpA
• Luminex Corporation
• Meridian Bioscience, Inc.
• Quidel Corporation
• Roche Diagnostics (Schweiz) AG
• Siemens AG
• Thermo Fisher Scientific, Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. Show more